Key result
Platelet-derived vesicles may serve as a predictive biomarker for thromboembolic complications in patients with atrial fibrillation, though current evidence is limited.
Why the study?
The role of platelet-derived micro vesicles as a predictive biomarker in AF needed to be discussed.
Can serial measures of circulating platelet-derived vesicles stratify the risk of thromboembolic complications in patients with atrial fibrillation?
Can serial measures of circulating platelet-derived vesicles stratify the risk of thromboembolic complications in patients with atrial fibrillation?
Platelet-derived vesicles are a potential but currently unproven biomarker for stratifying thromboembolic risk in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Platelet-derived vesicles remain an unproven AF biomarker; leaves open whether serial measures improve thromboembolic risk stratification.
Platelet vesiculation is common factor contributing in coagulation and thromboembolism in patients with atrial fibrillation (AF). Platelet-derived vesicles are involved in the coagulation, thromboembolism, microvascular inflammation, arterial stiffness, vascular calcification, atherosclerotic plaque shaping and rupture, endothelial dysfunction, cardiac remodelling, and kidney dysfunction. Recent clinical studies have revealed elevated concentrations of platelet-derived vesicles in peripheral blood of patients with current AF and history of AF. The aim of the mini review is to discuss the role of platelet-derived micro vesicles as predictive biomarker in AF. Serial measures of circulating levels of platelet-derived vesicules are discussed to be useful in stratification of AF patients at risk of thromboembolic complications, but there is limiting evidence regarding their predictive value that requires further investigations in large clinical trials.
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2019) conducted a review in Atrial fibrillation. Platelet-derived vesicles was evaluated. Platelet-derived vesicles may serve as a predictive biomarker for thromboembolic complications in patients with atrial fibrillation, though current evidence is limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: